{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:04:49Z","timestamp":1778742289217,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The safety of hypoglycemic drugs should be paid more attention to in elderly patients with type 2 diabetes mellitus due to their concomitant diseases, physiological decline of liver and kidney function and cognitive decline. The aim of this study was to evaluate the efficacy and safety of DPP-4 inhibitors in elderly patients with type 2 diabetes mellitus.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>From January 2010 to November 2018, 300 patients with type 2 diabetes mellitus who were over 60\u00a0years old were enrolled in the outpatient clinic of Geriatric Medical Center. Their medication records and follow-up medical records were used for retrospective analysis. The duration of treatment with DPP-4 inhibitors was more than 3\u00a0months. The changes of fasting blood glucose (GLU), glycosylated hemoglobin (HbA1C), body weight, body mass index (BMI) and liver and kidney function were compared before and after treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The average age of 300 patients (212 males and 88 females) was 73.7\u2009\u00b1\u20099.1\u00a0years old, BMI was 26.5\u2009\u00b1\u20092.8\u00a0kg\/m<jats:sup>2<\/jats:sup> and the duration of diabetes was 10.7\u2009\u00b1\u20098.2\u00a0years. The results of retrospective analysis showed that HbA1C decreased by 0.27% after treatment (P\u2009&lt;\u20090.001). In the group of DPP-4 inhibitors used for less than 12\u00a0months, there was no difference in liver transaminase (ALT and AST) between before and after treatment, whereas in the group of DPP-4 inhibitors used formore than 12\u00a0months, liver transaminase decreased statistically compared with after treatment (P\u2009&lt;\u20090.001). The incidence of fatty liver in elderly diabetic patients decreased after using DPP-4 inhibitors. There was no significant change in serum creatinine level and creatinine clearance rate in elderly patients with type 2 diabetes mellitus after treatment of DPP-4 inhibitor. In addition, the body weight and BMI of the patients decreased significantly (P\u2009&lt;\u20090.001). No hypoglycemic reaction and gastrointestinal discomfort were found in the medical records.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>After DPP-4 inhibitors were used in elderly patients with type 2 diabetes mellitus, the elevated glycosylated hemoglobin could be controlled with improved safety of liver and kidney, and might have the effect of weight loss.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13098-020-00543-1","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T11:02:51Z","timestamp":1588158171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus"],"prefix":"10.1186","volume":"12","author":[{"given":"Dong-Ni","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shang-Yong","family":"Ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Xin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,29]]},"reference":[{"key":"543_CR1","volume-title":"IDF diabetes atlas","author":"International Diabetes Federation","year":"2017","unstructured":"International Diabetes Federation. IDF diabetes atlas. 8th ed. Brussels: International Diabetes Federation; 2017.","edition":"8"},{"issue":"9","key":"543_CR2","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jama.2013.168118","volume":"310","author":"Y Xu","year":"2013","unstructured":"Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310(9):948\u201359.","journal-title":"JAMA"},{"issue":"3","key":"543_CR3","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.diabres.2014.03.005","volume":"103","author":"T Dunning","year":"2014","unstructured":"Dunning T, Sinclair A, Colagiuri S. New IDF Guideline for managing type 2 diabetes in older people. Diabetes Res Clin Pract. 2014;103(3):538\u201340.","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"543_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.pop.2017.04.011","volume":"44","author":"R Gopalraj","year":"2017","unstructured":"Gopalraj R. The older adult with diabetes and the busy clinicians. Prim Care. 2017;44(3):469\u201379.","journal-title":"Prim Care"},{"key":"543_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.diabres.2016.12.010","volume":"123","author":"AT Isik","year":"2017","unstructured":"Isik AT, Soysal P, Yay A, Usarel C. The\u00a0effects\u00a0of\u00a0sitagliptin, a\u00a0DPP-4\u00a0inhibitor, on\u00a0cognitive functions\u00a0in\u00a0elderly\u00a0diabetic\u00a0patients\u00a0with or without\u00a0Alzheimer\u2019s disease. Diabetes Res Clin Pract. 2017;123:192\u20138.","journal-title":"Diabetes Res Clin Pract"},{"key":"543_CR6","doi-asserted-by":"publisher","first-page":"104013","DOI":"10.1016\/j.archger.2020.104013","volume":"88","author":"E Ates Bulut","year":"2020","unstructured":"Ates Bulut E, Sahin Alak ZY, Dokuzlar O, et al. Cognitive and metabolic outcomes of\u00a0vildagliptin\u00a0addition\u00a0to the therapy in patients with type\u00a02 diabetes mellitus:\u00a026\u00a0week\u00a0follow-up\u00a0study. Arch Gerontol Geriatr. 2020;88:104013.","journal-title":"Arch Gerontol Geriatr"},{"issue":"1","key":"543_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.7326\/0003-4819-154-1-201101040-00003","volume":"154","author":"M Tonelli","year":"2011","unstructured":"Tonelli M, Muntner P, Lloyd A, et al. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med. 2011;154(1):12\u201321.","journal-title":"Ann Intern Med"},{"issue":"2","key":"543_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1136\/svn-2018-000203","volume":"4","author":"L Zhang","year":"2019","unstructured":"Zhang L, Chopp M, Jiang Q, Zhang Z. Role of the glymphatic system in ageing and diabetes mellitus impaired cognitive function. Stroke Vasc Neurol. 2019;4(2):90\u20132.","journal-title":"Stroke Vasc Neurol."},{"issue":"5","key":"543_CR9","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1185\/03007995.2011.568059","volume":"27","author":"N Barzilai","year":"2011","unstructured":"Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27(5):1049\u201358.","journal-title":"Curr Med Res Opin"},{"key":"543_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/ph11040121","volume":"11","author":"M Tacelli","year":"2018","unstructured":"Tacelli M, Celsa C, Magro B, et al. Antidiabetic drugs in NAFLD: the accomplishment of two goals at once? Pharmaceuticals (Basel). 2018;11:4.","journal-title":"Pharmaceuticals (Basel)."},{"issue":"2","key":"543_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3892\/br.2016.569","volume":"4","author":"T Mashitani","year":"2016","unstructured":"Mashitani T, Noguchi R, Okura Y, et al. Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. Biomed Rep. 2016;4(2):183\u20137.","journal-title":"Biomed Rep."},{"issue":"3","key":"543_CR12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1053\/j.ajkd.2005.05.027","volume":"46","author":"UD Patel","year":"2005","unstructured":"Patel UD, Young EW, Ojo AO, Hayward RA. CKD progression and mortality among older patients with diabetes. Am J Kidney Dis. 2005;46(3):406\u201314.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"543_CR13","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.2337\/dc16-1415","volume":"39","author":"JH Cornel","year":"2016","unstructured":"Cornel JH, Bakris GL, Stevens SR, et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS. Diabetes Care. 2016;39(12):2304\u201310.","journal-title":"Diabetes Care"},{"issue":"1","key":"543_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2337\/dc16-0621","volume":"40","author":"O Mosenzon","year":"2017","unstructured":"Mosenzon O, Leibowitz G, Bhatt DL, et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care. 2017;40(1):69\u201376.","journal-title":"Diabetes Care"},{"issue":"3","key":"543_CR15","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1053\/j.ajkd.2013.05.026","volume":"62","author":"JC Arjona Ferreira","year":"2013","unstructured":"Arjona Ferreira JC, Golm GT, Goldstein BJ. Primary objective of study of sitagliptin in patients with ESRD on dialysis. Am J Kidney Dis. 2013;62(3):642.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"543_CR16","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1002\/oby.20833","volume":"22","author":"R Nistala","year":"2014","unstructured":"Nistala R, Habibi J, Aroor A, et al. DPP-4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat. Obesity (Silver Spring). 2014;22(10):2172\u20139.","journal-title":"Obesity (Silver Spring)."},{"issue":"1","key":"543_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/01.mnh.0000437542.77175.a0","volume":"23","author":"K von Websky","year":"2014","unstructured":"von Websky K, Reichetzeder C, Hocher B. Physiology and pathophysiology of incretins in the kidney. Curr Opin Nephrol Hypertens. 2014;23(1):54\u201360.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"543_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrneph.2013.272","volume":"10","author":"MH Muskiet","year":"2014","unstructured":"Muskiet MH, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol. 2014;10(2):88\u2013103.","journal-title":"Nat Rev Nephrol."},{"key":"543_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev.nutr.22.010402.102715","volume":"22","author":"CW Bales","year":"2002","unstructured":"Bales CW, Ritchie CS. Sarcopenia, weight loss, and nutritional frailty in the elderly. Annu Rev Nutr. 2002;22:309\u201323.","journal-title":"Annu Rev Nutr"},{"issue":"1","key":"543_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S2213-8587(13)70021-4","volume":"2","author":"W Yang","year":"2014","unstructured":"Yang W, Liu J, Shan Z, et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2014;2(1):46\u201355.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"543_CR21","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/ijo.2013.162","volume":"38","author":"J van Can","year":"2014","unstructured":"van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014;38(6):784\u201393.","journal-title":"Int J Obes (Lond)."}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-020-00543-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-020-00543-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-020-00543-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:08:45Z","timestamp":1619654925000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-020-00543-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,29]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["543"],"URL":"https:\/\/doi.org\/10.1186\/s13098-020-00543-1","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,29]]},"assertion":[{"value":"19 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was approved by The Institutional Review Board of Ethics Committee of Beijing Hospital. All participants received written and oral information prior to giving written consent, and the study was performed in accordance with the Helsinki II declaration.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}